Skip to main content
Premium Trial:

Request an Annual Quote

Decision Biomarkers Raises $7.6M in Series A Funding

NEW YORK, Feb. 7 (GenomeWeb News) - Decision Biomarkers closed a $7.6-million Series A financing round, the company said Friday.


Oxford Bioscience Partners led the round. Investors included Rock Maple Ventures, Fletcher Spaght Venture Partners, and a group of individual investors led by Coco Montagu.


The company said it would use the capital to "fast-track" its technology for reducing "overall drug development costs."


"This funding will be used to complete the product launch and achieve early sales," said CEO Roger Dowd in a statement.


The Waltham, Mass.-based company makes a fully automated platform that enables researchers to test up to 40 biomarkers at one time.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.